SYS-CON MEDIA Authors: Eric Brown, Bob Gourley, Sandi Mappic, RealWire News Distribution, Kevin Benedict

News Feed Item

Kindred Bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option

SAN FRANCISCO, April 8, 2014 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. Kindred Bio estimates net proceeds from the offering to be approximately $58.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Kindred Bio intends to use the net proceeds of the offering for potential acquisitions of additional product candidates or other complementary assets or businesses, to accelerate and expand the research and development of its current product candidates, and for general corporate and working capital purposes.

Leerink Partners LLC acted as lead book-running manager, with BMO Capital Markets Corp. and Guggenheim Securities, LLC acting as active joint book-running managers for the offering.

The offering is being made only by means of a prospectus. Copies of the prospectus related to the offering may be obtained from Leerink Partners LLC at Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA, 02110, or by phone at 1-800-808-7525, ext. 4814, or by email at [email protected], BMO Capital Markets at Attention: Equity Syndicate Department, 3 Times Square, 27th Floor, New York, NY 10036, or by telephone at (800) 414-3627, or by email to [email protected], or from Guggenheim Securities, LLC at Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9349, or by email to [email protected].

This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About Kindred Biosciences

Kindred Biosciences is a development stage biopharmaceutical company focused on saving and improving the lives of pets.  Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy.  The Company's strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses.  The Company's lead product candidates are CereKin™ (diacerein) for the treatment of osteoarthritis pain and inflammation in dogs, AtoKin™ (fexofenadine) for the treatment of atopic dermatitis in dogs, and SentiKin™ (flupirtine) for the treatment of post-operative pain in dogs.

Forward-Looking Statements

Forward-looking statements in this news release involve inherent risks and uncertainties, and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to, uncertainties inherent in animal drug development and the regulatory review process and other risks described in the prospectus relating to the offering and in the Company's Annual Report on Form 10-K filed on March 14, 2014 with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date of this news release.

Contact
Denise Bevers
Kindred Bio
[email protected]
(650) 701-7909

SOURCE Kindred Biosciences, Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.